The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers drawn from the Forzinity prescribing information and FDA’s accelerated approval letter, and added the Federal Register notice of the 2024 advisory committee meeting. 32
What this version reported
The approval rests on muscle-strength increases seen in the open-label extension of a 12-person trial that missed its main goals. FDA requires a randomized confirmatory trial and may withdraw the approval if benefit is not verified.↗↗
Trial records: NCT07531251
Reader guide in this version
Key takeaway
Elamipretide is the active ingredient in Forzinity from Stealth BioTherapeutics. The label describes it as a mitochondrial cardiolipin binder that acts on the inner membrane of mitochondria, the energy-producing parts of cells.2,3 FDA granted it accelerated approval on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome, a rare genetic disease, who weigh at least 30 kg.2,3 The approval rests on an improvement in knee muscle strength, an intermediate measure, seen in the open-label extension of a 12-person trial that did not meet its main goals. FDA requires a confirmatory randomized trial.2,3
At a glance
- What it is
- A peptide that the label describes as a mitochondrial cardiolipin binder that improves mitochondrial structure and function.3
- FDA status
- FDA-approved. FDA’s September 19, 2025 accelerated approval letter approves Forzinity for a specified Barth syndrome population and requires a trial to verify clinical benefit. The label has no boxed warning.2,3
- Human evidence
- One small randomized, placebo-controlled crossover trial in 12 people that missed its main goals, followed by an open-label extension, as described in the label.3
- Evidence strength
- Smaller controlled human trials
What is elamipretide?
Elamipretide is the active ingredient of Forzinity. The label describes it as a mitochondrial cardiolipin binder, isolated as a hydrochloride salt.3
It is also known by the development names SS-31 and MTP-131.1
FDA’s approval letter is addressed to Stealth BioTherapeutics for application NDA 215244.2
How does elamipretide work?
The label describes Forzinity as a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial structure and function.3
The label states that the approval is based on an improvement in knee muscle strength, which it calls an intermediate clinical endpoint, rather than on a direct measure of how people feel or function.3
What do human studies show?
The label describes a randomized, double-blind, placebo-controlled crossover trial in 12 people aged 12 or older with genetically confirmed Barth syndrome. Elamipretide was not superior to placebo on the main outcomes, the 6-minute walk distance and a fatigue score.3
Knee muscle strength did not increase during the randomized trial, but increases were observed during the open-label extension, according to the label. Ten participants entered the extension and eight took part through week 168.3
The label presents the extension results as descriptive changes from the starting measurement, without a placebo comparison.3
What the evidence base contains
- Controlled human trial A randomized, double-blind, placebo-controlled crossover trial in 12 people aged 12 or older with Barth syndrome. The label states that elamipretide was not superior to placebo on its main outcomes, walking distance and fatigue.3
- Small, short, or incompletely reported human study An open-label, single-arm extension in which 10 of those participants continued and 8 took part through week 168, with increases in knee muscle strength reported.3
- Registered trial without results A further Barth syndrome trial, 4TAZPower (NCT07531251), sponsored by Stealth BioTherapeutics and listed as recruiting in its July 13, 2026 registry record.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is elamipretide FDA-approved?
A Federal Register notice announced that an FDA advisory committee would discuss the elamipretide application for Barth syndrome at an October 10, 2024 meeting.4
Yes, under accelerated approval. FDA’s letter of September 19, 2025 grants Forzinity accelerated approval, effective on the date of the letter, under FDA’s accelerated approval rules.2
The Forzinity label cited here (revised September 2025) states that it is indicated to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg, and that continued approval may depend on a confirmatory trial.3
The approval letter requires a randomized, double-blind, placebo-controlled trial in people aged 5 and older with Barth syndrome to verify the clinical benefit, and states that FDA may withdraw the approval if the trial fails to do so. FDA also granted a rare pediatric disease priority review voucher.2
The label has no boxed warning. It states that Forzinity is contraindicated in people with serious allergic reactions to it, and its warnings cover allergic reactions and the risk of benzyl alcohol toxicity in newborns; it is not approved for newborns.3
Timeline
- A Federal Register notice announces an October 10, 2024 FDA advisory committee meeting on the elamipretide application for Barth syndrome.4
- FDA grants Forzinity accelerated approval for a specified Barth syndrome population.2
- The 4TAZPower trial record is updated on ClinicalTrials.gov, listing the trial as recruiting.1
What is still unknown?
Whether the improvement in muscle strength translates into clinical benefit, which FDA’s required confirmatory trial is meant to show.2,3
Its effects in people outside the approved group: the label covers Barth syndrome in people weighing at least 30 kg.3
Results of the 4TAZPower trial, which was recruiting in its July 13, 2026 registry record.1
Sources for this version
- 14TAZPower: Elamipretide in Participants With Barth Syndrome · record history version 4 · last update posted 2026-07-13 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2Forzinity (elamipretide): NDA 215244 accelerated approval letter, September 19, 2025 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 3FORZINITY, revised September 2025: U.S. prescribing information ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 4Federal Register notice 2024-20062 · published 2024-09-06 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection ↗
Federal Register via GovInfo · Official source · Source checked August 21, 2026